Ensign Peak Advisors
RAPP

Ensign Peak Advisors’s Rapport Therapeutics RAPP Stock Holding History

Ensign Peak Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.9M Sell
165,546
-28,654
-15% -$1.05M 0.01% 501
2026
Q1 		$6.08M Hold
194,200
– – 0.01% 495
2025
Q4 		$5.89M Hold
194,200
– – 0.01% 496
2025
Q3 		$5.77M Hold
194,200
– – 0.01% 563
2025
Q2 		$2.21M Hold
194,200
– – ﹤0.01% 865
2025
Q1 		$1.95M Buy
+194,200
New +$2.52M ﹤0.01% 908

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Ensign Peak Advisors's RAPP Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Rapport Therapeutics (RAPP) stake by 15% in Q2 2026, selling an estimated $1.05M and leaving 165,546 shares worth $6.9M. The position accounts for 0.01% of the portfolio, ranked #501.

Ensign Peak Advisors first reported a position in RAPP in Q1 2025 and has held it in 6 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Ensign Peak Advisors held 165,546 shares of Rapport Therapeutics worth $6.9M as of Q2 2026.
  • Ensign Peak Advisors sold 28,654 Rapport Therapeutics shares in Q2 2026, an estimated $1.05M.
  • Rapport Therapeutics made up 0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #501 holding.
  • Ensign Peak Advisors first reported a position in Rapport Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.